Stock comparison
Medtronic
MDT
Market cap
$104.85B
Sector
Healthcare
Overall winner
Regeneron Pharmaceuticals
MDT 0–7 REGN
Regeneron Pharmaceuticals
REGN
Market cap
$66.62B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
MDTvsREGN
58D
64C
65B
68B
42D
48D
23F
26F
38D
45D
50D
59C
51D
57C
Side-by-side metrics
| Metric | MDT | REGN |
|---|---|---|
| Market cap | $104.85B | $66.62B |
| P/E (TTM) | 21.8x | 16.4x |
| EV/EBIT | 20.4x | 20.0x |
| ROIC (TTM) | 6.2% | 8.53% |
| Gross margin | 65.02% | 84.55% |
| Net margin | 13.2% | 29.65% |
| Revenue CAGR 5y | 3.5% | -2.81% |
| EPS CAGR 5y | 0.0% | -13.35% |
| Debt / Equity | 0.6x | 0.1x |
| Dividend yield | 3.48% | 0.51% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MDT leads on
- Revenue CAGR 5y3.5%vs -2.81%+180%
- EPS CAGR 5y0.0%vs -13.35%+100%
- Dividend yield3.48%vs 0.51%+85%
- Market cap$104.85Bvs $66.62B+36%
REGN leads on
- Debt / Equity0.1xvs 0.6x+85%
- Net margin29.65%vs 13.2%+55%
- ROIC (TTM)8.53%vs 6.2%+27%
- P/E (TTM)16.4xvs 21.8x+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.